A case with68ga-fapi positive and18f-fdg negative breast cancer 68 ga-fapi pozitif,18f-fdg negatif meme kanseri olgusu

---

Kömek H., Gündoğan C., Etem H., Can C.

Molecular Imaging and Radionuclide Therapy, cilt.30, sa.3, ss.201-204, 2021 (ESCI, Scopus, TRDizin)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 30 Sayı: 3
• Basım Tarihi: 2021
• Doi Numarası: 10.4274/mirt.galenos.2021.69926
• Dergi Adı: Molecular Imaging and Radionuclide Therapy
• Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
• Sayfa Sayıları: ss.201-204
• Anahtar Kelimeler: Ga-68-FAPI, F-18-FDG, PET/CT, breast cancer, PATIENT
• Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
• Gazi Üniversitesi Adresli: Hayır

Özet

© 2021 by Turkish Society of Nuclear Medicine Molecular Imaging and Radionuclide Therapy published by Galenos Yayınevi.A female patient diagnosed of infiltrative breast carcinoma using tru-cut biopsy underwent18flourine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for staging. The tumor was located in the superior external quadrant of the right breast, and did not exhibit pathological uptake in18F-FDG PET/CT. Later, gallium-68 (68Ga) fibroblast activation protein-specific inhibitor (FAPI)-04 PET/ CT imaging was performed and the primary tumor showed intense radiotracer accumulation. This presumes that68Ga-FAPI PET/CT imaging is superior to18F-FDG imaging in detecting the primary tumor in breast cancer, thereby suggesting the replacement of FAPI by18F-FDG in breast-cancer staging in the future.